NodThera, the leading clinical-stage NLRP3 company developing a portfolio of best-in-class brain-penetrant and immune-targeted oral inhibitors to address cardiometabolic and neuroinflammatory diseases ...
CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that managem ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results